All In Biotech

Drug Trial Radar · NCT07920354

Comparative Efficacy of Luliconazole and Bifonazole Combined With Itraconazole in Dermatophytosis

Effectiveness of Topical Luliconazole With Oral Itraconazole Versus Topical Bifonazole With Oral Itraconazole in Patients With Dermatophytosis: A Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 182 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

182

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
University of FaisalabadAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this randomized controlled trial is to compare the efficacy of topical luliconazole with topical bifonazole in adults aged 18-60 years with dermatophytosis. All participants will receive oral itraconazole, while either topical luliconazole or topical bifonazole will be added according to their assigned treatment group. The main questions it aims to answer are: * Does topical luliconazole result in greater improvement in clinical severity, as measured by the DeASI score, compared with topical bifonazole? * Does topical luliconazole result in better mycological clearance on 10% KOH microscopy and lower relapse compared with topical bifonazole? Researchers will compare topical luliconazole with topical bifonazole, with oral itraconazole given to both groups, to assess differences in clinical improvement, mycological cure, and relapse. Participants will: * Receive oral itraconazole 100 mg once daily together with either topical luliconazole 1% or topical bifonazole 1% once daily for 28 days. * Attend follow-up visits at weeks 2, 4, and 6 for clinical assessment, DeASI scoring, and 10% KOH microscopy.

Conditions

  • Tinea Corporis
  • Tinea Cruris
  • Tinea Faciei

Interventions

  • ItraconazoleDrug

    Itraconazole 100 mg orally twice daily for 28 days. It will be administered to participants in both treatment groups.

  • Luliconazole Cream 1%Drug

    Luliconazole 1% cream applied topically once daily for 28 days to the affected areas.

  • Bifonazole cream 1%Drug

    Bifonazole 1% cream applied topically once daily for 28 days to the affected areas.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in DeASI score from baseline to Week 4Time frame: Baseline to Week 4

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Madinah Teaching Hospital

    Faisalabad, Punjab Province, Pakistan

  • Madinah Teaching Hospital

    Faisalabad, Punjab Province, Pakistan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.